Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Peptide Vaccination for the Treatment of Patients With Solid Tumors Moderately Expressing HER2/Neu

NCT02276300 is registered in ClinicalTrials.gov with Technical University of Munich as lead sponsor.

NCT NCT02276300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02276300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Peptide Vaccination for the Treatment of Patients With Solid Tumors Moderately Expressing HER2/Neu
Lead sponsor
Technical University of Munich
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2014
Completion date
July 13, 2018
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastric cancer